|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In Korea, where PTC comprises about 90-95% of the reported thyroid cancers, the prevalence of BRAF(V600E) mutation in papillary thyroid carcinoma (PTC) is above 80%.
|
21239517 |
2011 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this article, we review the pathogenesis of PTC, and the clinical implications of BRAF(V600E) mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancers.
|
20230995 |
2010 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
|
20498063 |
2010 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines harboring BRAF V600E (8505C, BCPAP, SW1736, BHT101), NRAS Q61R (HTH7), KRAS G12R (CAL62), HRAS G13R (C643), or RET/PTC1 (TPC-1) oncogenes.
|
19880792 |
2010 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-Raf(V600E) mutation in thyroid cancer.
|
20637346 |
2010 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangements have been disclosed also in non malignant thyroid lesions and their biological significance is debated.
|
21048359 |
2010 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results in thyroid cancer cells, namely those harbouring BRAF(V600E) mutation showed that BRAF signalling pathway provides important proliferation signals.
|
19878585 |
2009 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroid cancer and melanoma.
|
18462259 |
2009 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samples and studied prospectively blood samples from 193 patients with thyroid cancer (173 PTC, 20 non-PTC) attending for routine follow-up.
|
19850689 |
2009 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers.
|
18310287 |
2008 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked drop in thyroperoxidase (29-fold) and pendrin (20-fold) expression and a considerable increase (five-fold) in GLUT-1 expression.
|
17854396 |
2008 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
|
17714762 |
2007 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
|
17387744 |
2007 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers.
|
17054470 |
2006 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
|
15272920 |
2004 |
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |